Chang J, et al. - In this retrospective study involving 70 patients, 30 of whom had allogeneic hematopoietic stem cell transplantation (HSCT) and 40 who received only chemotherapy plus dasatinib, researchers examined the outcomes of adult patients with Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) treated with either combination chemotherapy plus dasatinib or combination chemotherapy plus dasatinib followed by allogeneic HSCT. While a survival advantage in Ph+ ALL was previously seen with HSCT, these outcomes show that those benefits may be diminished in the time of newer tyrosine kinase inhibitors like dasatinib. A 3-year OS of 76% vs 71.3% was seen in the transplant vs nontransplant groups, respectively.